A case of rituximab-induced hepatitis

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 6, 2010, Pages 747-748

  Del Prete, Christopher Joseph ^a   Cohen, Neil S ^a,b  

^a Carl and Dorothy Bennett Cancer Ctr   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

biotherapy; chemotherapy

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; IMMUNOGLOBULIN; PARACETAMOL; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; TOXIC HEPATITIS;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG-INDUCED LIVER INJURY; HUMANS; IMMUNOLOGIC FACTORS; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 78651311718     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0806     Document Type: Article

References (6)

1. Bromberg M. Immune thrombocytopenic purpura\the chang-ing therapeutic landscape. N EnglJ Med 2006;255:1643.
2. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dex-amethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010;115:2755.
3. Ling H, Field J, Blinder M. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: A report of 13 cases and review of the literature. Am J Hematol 2009;84:418.
4. Arnold D, Dentali F, Crowther M, et al. Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25.
5. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lym-phoma 2007;48:1307.
6. Final Labeling Text for Rituximab. Online document at www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf Accessed June 6, 2010.